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ABSTRACT   40 
Background and Aim 41 
Coronary heart disease (CHD) is the commonest cause of death in the UK, causing 42 
over 120,000 deaths in 2001, amongst the highest rates in the world.  This study 43 
reports an economic evaluation of Single Photon Emission Computed Tomography 44 
myocardial perfusion scintigraphy (SPECT) for the diagnosis and management of 45 
coronary artery Disease (CAD).  46 
 47 
Methods 48 
Strategies involving SPECT with and without Stress Electrocardiography (EGC), and 49 
Coronary Angiography, were compared to diagnostic strategies not involving 50 
SPECT.  The diagnosis decision was modelled with a Decision Tree Model and long-51 
term costs and consequences using a Markov Model. Data to populate the models 52 
were obtained from a series of systematic reviews. Unlike earlier evaluations, a 53 
probabilistic analysis was included to assess the statistical imprecision of the results.  54 
The results were presented in terms of incremental cost per quality adjusted life year 55 
(QALY). 56 
 57 
Results  58 
At prevalence levels of CAD of 10.5%, SPECT-based strategies are cost effective; 59 
ECG-CA is highly unlikely to be optimal. At a ceiling ratio of £20,000 per QALY, 60 
SPECT-CA has a 90% likelihood of being optimal. Beyond this threshold this strategy 61 
becomes less likely to be cost-effective.  At over £75,000 per QALY, coronary 62 
angiography is most likely to be optimal. For higher levels of prevalence (around 63 
50%) and more than a £10,000 per QALY threshold, coronary angiography is the 64 
optimal decision. 65 
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Conclusion 66 
SPECT-based strategies are likely to be cost-effective when risk of CAD is modest 67 
(10.5%). Sensitivity analyses show these strategies dominated non-SPECT based 68 
strategies when risk of CAD for up to 4%. At higher levels of prevalence invasive 69 
strategies may become worthwhile. Finally, sensitivity analyses show stress ECHO as 70 
a potentially cost effective option and further research to assess the relative cost-71 
effectiveness of ECHO should also be performed. 72 
 73 
KEYWORDS 74 
Coronary heart disease, coronary artery disease, cost-utility analyses, probabilistic 75 
sensitivity analysis. 76 
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INTRODUCTION 77 
Coronary heart disease (CHD) is the commonest cause of death in the UK, causing 78 
over 120,000 deaths in 2001.  Death rates have been falling in the UK since the late 79 
1970s.  However, despite this improvement, death rates are still amongst the highest 80 
in the world. Morbidity, in contrast to mortality, is rising with over 378,000 inpatient 81 
cases treated for CHD in UK NHS hospitals in 2000/2001, representing 5% of all 82 
inpatient cases in men and 2% in women.(1)  The cost of CHD to the UK health care 83 
system in 1999 was estimated as £1.73 billion rising to £7.06 billion when informal 84 
care and productivity losses were included.(2)  85 
 86 
Coronary artery disease (CAD) is the most common cause of CHD, with most CAD 87 
caused by the narrowing of the large and medium sized arteries serving the heart.  88 
Methods of detecting and assessing the presence and extent of CAD have become 89 
increasingly important in applying therapies to reduce morbidity and mortality.  90 
Coronary angiography is considered the “gold standard” for defining the site and 91 
severity of coronary artery lesions but it is costly and associated with significant risk 92 
of mortality and morbidity and not recommended without prior non-invasive 93 
testing. 94 
 95 
Of the non-invasive tests available the most widely used, due its relatively low cost 96 
and availability, is stress (induced by either exercise or pharmacological agents) 97 
electrocardiography (ECG). However, a normal stress ECG does not exclude CAD.  98 
Furthermore, it performs poorly in low-risk populations.(3) Imaging techniques such 99 
as myocardial perfusion scintigraphy (MPS) can also be used to improve detection 100 
and/or localisation of CAD.  MPS uses an intravenously administered 101 
radiopharmaceutical to evaluate regional coronary flow after stress and at rest.  In 102 
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single photon emission computed tomography (SPECT), the raw data are then 103 
processed to obtain tomographic images.   104 
 105 
These non-invasive tests can be used either alone or in combination but it is not clear 106 
which of the possible diagnostic strategies that could be devised would be most 107 
efficient.  This is an issue that has been addressed by a number of earlier economic 108 
evaluations that have recently been systematically reviewed.(4)  This systematic 109 
review found that strategies involving SPECT were likely to be either dominant or 110 
produced more quality adjusted life years at an acceptable cost, relative to those that 111 
did not contain SPECT but that there was little consistency in the literature about 112 
which of the various strategies that involved SPECT was optimal.  The available 113 
economic evaluations were almost all conducted in a single country (the US) and 114 
their results may have limited transferability to other settings.  More importantly the 115 
results of all these evaluations were subject to considerable uncertainty which was 116 
addressed in only a limited fashion (if at all) by sensitivity analysis. Two particular 117 
shortcomings can be identified. First, the available economic evaluations relied on 118 
the results of either a single primary study, which may not be reliable and or 119 
generalisable, or a review of studies in which comparisons between the diagnostic 120 
performance of tests were based on indirect comparisons which may be prone to 121 
selection bias.  Second, where sensitivity analysis was conducted the methods used 122 
were not well suited to addressing the statistical uncertainty surrounding the data 123 
used in the study.(5)  124 
 125 
In this study an attempt has been made to overcome these limitations in an 126 
evaluation of which strategy for the diagnosis of CAD is most likely to be cost-127 
effective.  In particular, the evaluation compares alternative strategies involving 128 
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SPECT alone or in combination with other non-invasive tests with strategies that do 129 
not involve SPECT. 130 
 131 
METHODS 132 
Overview of the Model 133 
Economic Modelling techniques were used to compare diagnostic strategies 134 
including SPECT to strategies that did not. A two-stage model was developed. In the 135 
first stage, a decision tree model (DTM), constructed in Excel(6), was used for the 136 
diagnosis decision (Figure 1) and in the second stage a Markov Model, developed in 137 
Data 4.0(7),  was created to model longer term cost and consequences (Figure 2). 138 
Specifically, it considered the management of patients with suspected CAD. The 139 
model structure was developed following consultation with clinicians and 140 
consideration of the existing economic evaluation literature.(4)  141 
 142 
Decision Tree Model 143 
The DTM is a way of displaying the proper temporal and logical sequence of a 144 
clinical decision problem.(8) In practical terms, it may take weeks or even months for 145 
a patient to go from the first decision node to the final diagnosis. 146 
 147 
The tests considered in the DTM were SPECT, stress ECG and coronary angiography. 148 
These diagnostic tests were combined to produce the following strategies (thought, 149 
on the basis of the literature and clinical opinion, representative of current practice): 150 
a) Stress ECG; followed by SPECT if stress ECG positive or indeterminate; followed 151 
by coronary angiography if SPECT positive –high risk– result or indeterminate 152 
b) Stress ECG; followed by coronary angiography if stress ECG positive or 153 
indeterminate 154 
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c) SPECT; followed by coronary angiography if SPECT positive –high risk– result or 155 
indeterminate 156 
d) Coronary Angiography (invasive test as first option). 157 
 158 
Within the model (Figure 1) a patient may, for example, arrive in the hospital with 159 
typical chest pain. This is central chest discomfort often described as tightness, a 160 
weight on the chest or a constricting band around the chest; usually not sharp in 161 
nature and builds up and down slowly, varied in severity but lasts only a few 162 
minutes, frequently radiates down the left arm, up into the neck or through to the 163 
back. It can often be associated with cold sweat, breathlessness and tingling in the 164 
hands and/or fingers and pain would be relieved by resting. (Malcolm Metcalfe, 165 
personal communication, September 2006) 166 
 167 
Taking the patient’s history and symptoms into account the physician must decide 168 
between an invasive test (coronary angiography) and a non-invasive test as the first 169 
option (stress ECG or SPECT). If the physician decides on an invasive test, then the 170 
patient has a small risk of dying during the test. If the patient survives, then this will 171 
result in a final classification of their condition into one of three categories: High Risk 172 
(i.e. three vessel disease and poor left ventricular function or left main disease); 173 
Medium Risk (single or double vessel disease); or Low Risk, (no significant heart 174 
disease present).  175 
 176 
If the physician opts for the non-invasive stress ECG test as the first option, and if the 177 
result of this test is positive, another non-invasive test, SPECT, could be requested. If 178 
the SPECT test result is positive this might result in a diagnosis of the patient as High 179 
Risk or result in a request for a coronary angiography to help determine appropriate 180 
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management. A final outcome of this strategy for this particular patient would be if 181 
they receive a left main disease diagnosis following angiography and would be 182 
classified as High Risk. Similarly, if the SPECT results are negative then the physician 183 
classifies the patient as Low Risk. 184 
 185 
There are three possible diagnoses and three possible disease states. However, as all 186 
individuals that have a positive result would eventually go to a further test, all those 187 
diagnosed as high risk must have gone through coronary angiography as their last 188 
test (if coronary angiography is not their first and only test). As the model assumed 189 
perfect information from coronary angiography (i.e it is defined as a gold standard), 190 
there is no possibility of misclassifying patients identifies as being as high risk by a 191 
non-invasive test.   Thus, at the end of the Decision Tree a patient who has survived 192 
the diagnostic process will be in one of the following diagnostic situations: a) Low 193 
Risk; b) Medium Risk; c) High Risk; d) classified as low risk but actually high risk 194 
(false negative); e) classified as low risk but in fact medium risk (false negative); f) 195 
classified as medium risk but actually low risk (false positive); g) classified as 196 
medium risk but actually high risk. These outcomes represent the states in which the 197 
patient will start in the Markov model described below. 198 
 199 
Markov Model 200 
The Markov Model provides estimated costs and outcomes over a selected period of 201 
time (e.g. the expected lifetime) for cohort of patients for each of the different 202 
management strategies that could be adopted following diagnosis. A Markov Model 203 
of the type presented here has states in which patients stay for a period of time called 204 
a ‘cycle’. The cycle must be a period of time relevant to the condition considered (in 205 
this case one year). At the end of the cycle, the individuals can remain in the state 206 
Hernández, R.; Vale, L. : ”The value of myocardial perfusion scintigraphy…”  
 10 
they started the cycle in, or they can move to a different state. The probabilities of 207 
moving from one state to another are called transition probabilities and these are 208 
defined below. Finally, in these models there must be at least one absorbing state 209 
from which the patient will not be able to leave. In this model the absorbing state is 210 
‘death’ which can be reached from any of the other states. 211 
 212 
These Markov model states can be thought of as comprising a number of events that 213 
influence cost and outcome. For instance, patients entering a Medium Risk state 214 
(Figure 2) will receive medical management and will enjoy a particular quality of life 215 
during the period of time they remain in that state. If a patient has a revascularisation 216 
the model will adjust costs and quality of life. Patients who receive and survive a 217 
revascularisation move to a revascularisation state in which they enjoy the benefits of 218 
the revascularisation (lower risk of death and MI) until the patient dies or it is felt the 219 
benefits of the revascularisation will no longer be obtained. A similar process can be 220 
described for the other states (Figure 2).  221 
 222 
Interventions and events considered within the model are: for all states medical 223 
management and myocardial infarction. In addition, revascularisation (PTCA or 224 
CABG) is included for Low, Medium or High Risk states. For ’revascularisation‘ 225 
states, further revascularisation is possible. Finally, within the ’false‘ states part of the 226 
cohort may be re-diagnosed by coronary angiography. The assumption within the 227 
model is that all survivors are correctly diagnosed after a maximum of 10 years 228 
period either as a result of additional diagnostic tests or a non-fatal MI.  This 229 
assumption reflects the belief that ‘at risk’ individuals would over time face other 230 
opportunities, such as regular health checks, in which they may receive a correct 231 
diagnosis. 232 
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 233 
Probabilities 234 
Decision Tree Model Probabilities 235 
Decision tree probabilities were derived from the literature or calculated in the 236 
model. Medline (1966-October 2002), EMBASE (1980- October 2002) and also PRE-237 
MEDLINE and NHS-EED were searched with terms like ‘coronary disease’ or 238 
‘myocardial ischemia’ or ‘angina pectoris’ amongst others.  Further details of the 239 
search strategy adopted are described in Mowatt and colleagues, Appendix 1.(4) 240 
 241 
The prevalence of coronary heart disease (Table 1) was obtained from British Heart 242 
Foundation Statistics.(1) Sensitivity and specificity data were obtained from Mowatt 243 
and colleagues.(4) Mowatt and colleagues conducted a systematic review of 244 
diagnosis accuracy of SPECT, stress ECG and coronary angiography. This review 245 
only included studies that reported direct comparisons between the three tests as 246 
opposed to other reviews that relied on indirect comparisons between studies.(9-17) 247 
In the review by Mowatt and colleagues angiography was taken as the reference 248 
standard. Sensitivity and specificity figures were determined by the interpretation by 249 
the research team of the results of the review of effectiveness. 250 
 251 
In previous work it has been typically assumed that coronary angiography is the 252 
gold standard (sensitivity and specificity equal to 1).(4, 12, 15) Although it is known 253 
that coronary angiography is not a reliable indicator of the functional significance of 254 
coronary stenosis (3, 18) this study has assumed perfect information from coronary 255 
angiography but explored the issue in sensitivity analysis. 256 
 257 
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Using the prevalence data and data on sensitivity and specificity, positive and 258 
negative result rates were calculated for each diagnostic strategy. An assumption 259 
was made that sensitivity and specificity rates were independent of the underlying 260 
prevalence of CAD.  Incorporation of these data into the DTM allowed positive and 261 
negative result rates to be calculated for diagnostic strategy at different pre-test risks 262 
of CAD. 263 
 264 
Markov Model Probabilities 265 
The time horizon for the Markov Model was 25 years and the transition probabilities 266 
and their sources used in this model are presented in Table 1.  The risk of dying from 267 
any of the states was calculated as the mortality rate for the corresponding age group 268 
with adjustments for the relative risk caused by the level of risk and beneficial effects 269 
of medical or surgical treatment. The mortality rate for men and women for England 270 
and Wales was based on general population estimates produced by the UK 271 
Government’s Actuary Department.(19) 272 
 273 
Within the Markov model states were defined for both false negatives and false 274 
positives. The model allows for an increasing proportion of misclassified patients to 275 
be allocated properly in each cycle. As described above, for the base case the 276 
complete cohort of misclassified patients would be correctly allocated within 10 277 
years. 278 
 279 
The risk of MI is considered for each state. The risk for the general population, used 280 
for the Low Risk state, was obtained from Lampe and colleagues 2000.(20) This is a 281 
UK based prospective study to describe the long-term outcomes of ischemic heart 282 
disease that involved a sample of 7735 men aged 40 to 59. The relative risks for the 283 
Hernández, R.; Vale, L. : ”The value of myocardial perfusion scintigraphy…” 
 13 
other states were derived from the prospective USA based study by Shaw and 284 
colleagues 1999 (N=11,372).(21) These proportions were split into fatal and non-fatal 285 
MI using data from Lampe and colleagues(20) and Volmink and colleagues 286 
(population wide surveillance study based in Oxfordshire, UK) in order to correctly 287 
re-diagnose those who had a non-fatal MI.(22) 288 
 289 
Annual revascularisation risk in Medium and High risk states as well as risk of 290 
second revascularisation when having PTCA or CABG were derived from Kuntz and 291 
colleagues.(12)  292 
 293 
Costs 294 
Decision Tree Model Costs 295 
Table 1 shows the interventions considered for the Decision and Markov model, the 296 
cost in 2001/02 pounds sterling, and the sources from where the figures were 297 
obtained. 298 
 299 
The total costs for stress ECG and coronary angiography were £105(23) and 300 
£1310.(24)  The cost of stress ECG was calculated from HRG V05 category.(25)  It is 301 
Admission and Emergency direct cost plus a share of support services (pathology 302 
and radiology) and has been calculated in a top-down approach. 303 
 304 
The cost of SPECT came from Underwood and colleagues.(24)  Their figures were 305 
derived by averaging 1996 data for UK centres and Royal Brompton Hospital, 306 
London, which was judged to be the most meaningful by the authors. These costs 307 
were estimated using a very detailed bottom-up costing exercise where all resources 308 
were itemised and costed (personal communication, Professor Underwood, February 309 
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2003). The cost estimate was checked with an estimate derived using a top-down 310 
approach with data from different sources, which confirm the figures from the 311 
EMPIRE study.(24) The costs reported by Underwood and colleagues were inflated 312 
using the Hospital and Community Health Services (HCHS) Pay and Prices 313 
Index.(26)  314 
 315 
Markov Model Costs 316 
For the different Risk states three interventions were considered: medical 317 
management, MI event management and revascularisation.  Medical management 318 
cost for the different states was obtained from experts’ opinion and checked with the 319 
literature. It was found that the final figure did not differ much from the one 320 
presented by Sculpher and colleagues.(27) Prices for this calculation were obtained 321 
from the British National Formulary.(28) MI event management cost data came from 322 
Boland and colleagues(29), who used NHS Reference Costs(25); figures for 2001/02 323 
from the same source were used in this model. 324 
 325 
The cost for PTCA was £1994(23); the calculation assumed 60 minutes of theatre time, 326 
and an angiography performed immediately prior to the PTCA. The calculation 327 
allowed for the staff cost of five healthcare professionals as well as relevant 328 
consumables plus capital items. The cost for CABG was obtained from NHS 329 
Reference Costs.(25)  Where appropriate estimates were adjusted for inflation using 330 
HCHS Pay and Prices Index.(26) 331 
 332 
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Quality of life measures 333 
One of the products of the economic evaluation is quality adjusted life years 334 
(QALYs).  QALYs combine estimates of survival time and the quality of that survival 335 
time. Survival is provided by the cumulative number of cycles spent in each state of 336 
the model other than Death. Taking the time spent in each state and weighting it by a 337 
quality of life score provided an estimate of QALYs. 338 
 339 
Estimates of QALYs were required for each of the states in the Markov model.  The 340 
best data for estimation of this, given the perspective of the evaluation, would be UK 341 
studies with generic health status measures such as those provided by tools such as 342 
the EQ 5D.(30) In the absence of such data information was sought from a review of 343 
related economic evaluations(4) and from the Cost Effectiveness Analyses 344 
Registry.(31) While relatively comprehensive, the data presented in the registry were 345 
methodologically no better (and more often of lower quality) than the results of the 346 
standard gamble exercise used by Kuntz and colleagues(12) identified by a review of 347 
economic evaluations. The utility scores used in the model are described in Table 1. 348 
 349 
It was assumed in the Markov Model that patients who have an MI or are 350 
revascularised will lose part of their QALYs as a result of the event and will recover 351 
their previous level of quality of life in three months (Table 1).(32) The gain from 352 
revascularisation is the subsequent lower risk of death but not a higher quality of life 353 
than before revascularisation. 354 
 355 
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Data analysis 356 
The parameters for costs of interventions, risks of events and quality of life for the 357 
base case analysis were entered in decision tree and Markov models. Payoffs for the 358 
decision tree model were obtained from the Markov models run for up to 25 cycles 359 
(i.e., 25 years follow-up period). The starting age for the hypothetical cohort of 360 
patients was 60 years. Annual discount rates of 6% and 1.5% were used for costs and 361 
outcomes, respectively.(33) The costs and effects were re-estimated for different 362 
values of prevalence of disease: 10.5% (baseline), 30%, 50% and 85%. The baseline 363 
rate was calculated using data from the British Heart Foundation Statistics and is an 364 
estimation of the mean population CHD prevalence. Lower levels of prevalence were 365 
explored in sensitivity analyses. 366 
 367 
Sensitivity Analysis 368 
Manning and colleagues (5) developed a taxonomy of uncertainty in economic 369 
evaluations. They distinguished between ‘Modelling uncertainty’ from ‘parameter 370 
uncertainty’: the first could be further differentiated into uncertainty due to model 371 
structure and uncertainty due to the overall process of the cost-effectiveness analysis. 372 
Parameter uncertainty refers to those cases where the parameters could not be 373 
observed, for which there are disagreement about their appropriate values, or how 374 
they could change in the future (epidemiology of the disease), sampling variability, 375 
or values of parameters to feed the model for alternative settings. 376 
 377 
Probabilistic sensitivity analysis was used to address parameter uncertainty. The 378 
importance of this has been stressed elsewhere.(5, 34, 35) Prior probability 379 
distributions to allow for uncertainty in the mean parameters values were specified 380 
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following usual practice (34, 36) and are shown in Table 1.  Detailed information on 381 
costs was limited, nonetheless as a mean and range were available triangular 382 
distributions for costs were used.  For proportions, beta distributions were used (i.e. 383 
sensitivity or specificity of diagnosis tests).(37) Gamma distributions were used for 384 
probabilities that were very near to zero (i.e. death during an ECG test)(Alan 385 
Brennan, personal communication, April 2004)(38) and lognormal distributions were 386 
used for relative risks (i.e. relative risk of death for High Risk patients).(35) 387 
 388 
One thousand Monte Carlo simulation iterations were obtained for the Markov 389 
Payoff Model. These results were used as probability distributions for the payoffs in 390 
the Decision Tree Model. Monte Carlo Simulation was then performed in the 391 
Decision Tree Model using the Excel added on Crystal Ball software.(6, 39)  392 
 393 
These results were used for calculating credible intervals for the deterministic results 394 
presented in Table 2 and for constructing cost-effectiveness acceptability curves 395 
(CEACs). CEACs detail the probability that the intervention is optimal for any 396 
maximum value that the Decision Maker would be willing to pay (Ceiling Ratio) for 397 
an extra unit of effectiveness (in our case for an extra QALY).(40) 398 
 399 
While probabilistic sensitivity analysis allow us to know how precise the results in 400 
the model are, it could potentially give us a very precise wrong answer if the data 401 
used as inputs, in this case sensitivity and specificity of the tests, for instance, were 402 
potentially biased. Therefore, probabilistic sensitivity analysis was combined with 403 
other forms of sensitivity analysis.  Mowatt and colleagues(4) stated that there was 404 
heterogeneity between the studies that provided data on the specificity or sensitivity 405 
of the tests. Figures from some of these studies were used to address this potential 406 
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problem.  A similar problem also limited previous economic evaluations identified 407 
by the systematic review of economic evaluations(4), although it has not previously 408 
been elucidated. Furthermore, the uncertainty surrounding estimates of sensitivity 409 
and specificity used in earlier studies has been further compounded by potential 410 
biases caused by the indirect comparisons used. 411 
 412 
Other sensitivity analysis was also conducted. First the time horizon over which costs 413 
and effects are considered was varied from 25 to 10 and 5 years, as it may be 414 
unrealistic to assume that costs and outcomes over such a long period can be reliably 415 
estimated. Second, the period in which false negatives are correctly re-diagnosed has 416 
been modified from the maximum of 10 years assumed for the base case. Third, 417 
alternative data for the likelihood that a test was indeterminate were used.(12) Kuntz 418 
and colleagues assume higher values for ECG indeterminacy (30% vs. 18% base case) 419 
and lower value for SPECT indeterminacy (2% vs. 9% base case). Fourth, the analysis 420 
was repeated with a £25 and £225 cost for stress ECG, £128 and £340 cost for SPECT, 421 
and £895 and £1724 cost for coronary angiography based on data from Mowatt and 422 
colleagues.(4)  Finally, a sub-group analysis for female cohort has been performed 423 
which took data suggesting a lower prevalence of disease and slightly higher 424 
sensitivity and specificity for SPECT.(4)   425 
 426 
Average costs were used as the basis of estimates of costs for the diagnostic tests 427 
used. Such costs include elements for the capital and overheads of providing these 428 
services.  As there may be concerns that they do not adequately reflect opportunity 429 
costs, the impact of using these costs was also explored in the sensitivity analysis. 430 
 431 
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The generalisability of this analysis could be undermined due to exclusion of 432 
potentially relevant strategies for other settings. Particularly relevant seems to be the 433 
case of Echocardiography (ECHO) that appear to be a cost-effective option in 434 
previous studies.(12) Further sensitivity analysis was conducted and two strategies 435 
were added to the original model. Namely, ECHO followed by coronary 436 
angiography if ECHO positive result, and ECHO followed by SPECT if ECHO 437 
positive result, followed by coronary angiography if SPECT high-risk diagnostic 438 
result. Data needed to feed the model added strategies were obtained from Kuntz 439 
and colleagues(12) for ECHO sensitivity, specificity, and assumed the same 440 
indeterminacy and mortality rates as ECG(15), and probability distributions were 441 
attached for probabilistic analysis (Table 1). 442 
 443 
The prevalence rates used for the base case analysis might be considered high 444 
according to some sources.(41) This also could potentially undermine the 445 
generalisability and practical use of this study results to other settings. The original 446 
model was run for lower prevalence rates (e.g. 0.1%, 0.5%, 1% and 5%) as part of the 447 
sensitivity analysis. 448 
 449 
Finally, it is known that coronary angiography is not a reliable indicator of the 450 
functional significance of coronary stenosis(3, 18). Therefore, an additional 451 
probabilistic sensitivity analysis was performed assigning further probability 452 
distributions to the sensitivity and specificity of coronary angiography. Beta 453 
distributions were used with mean 0.99 and standard deviation of 0.005 for both 454 
parameters. 455 
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RESULTS 456 
Base case analyses 457 
Table 2 show the deterministic results of the base case analysis and a range of 458 
different prevalence rates. As prevalence increases, cost increases and QALYs 459 
decrease.  At all prevalence levels the order of the strategies remain the same. This 460 
table also shows the incremental cost per QALY. This outcome is based upon 461 
diagnostic and treatment costs (obtained from the payoff model) and estimated 462 
QALYs.  As a consequence, the incremental cost per QALY is driven, not only by 463 
diagnostic performance, but also the costs and consequences of management 464 
strategies chosen on the basis of diagnostic information.  465 
 466 
For a prevalence of 10.5% the incremental cost per QALY gained (ICER) for the move 467 
from SPECT-coronary angiography strategy to coronary angiography strategy is 468 
£48,600.  ECG-SPECT-coronary angiography and SPECT-coronary angiography 469 
strategies have extended dominance over the ECG-coronary angiography strategy 470 
(i.e. managing patients with a combination of ECG-SPECT-coronary angiography 471 
and SPECT-coronary angiography would result in a lower incremental cost per 472 
QALY than managing all patients with the ECG-coronary angiography strategy 473 
alone).  This is because the ICER for movement from ECG-SPECT-coronary 474 
angiography to ECG-coronary angiography (£26,249) is higher than going from ECG-475 
coronary angiography to SPECT-coronary angiography (£9261)). The ICER without 476 
the extended dominated strategy is £15,241.  477 
 478 
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At a 30% prevalence level the order of the strategies is the same but the ICERs 479 
associated with movement between the strategies fall. The situation of extended 480 
dominance described above persists.  481 
 482 
At a prevalence level of 50% the ICER for moving from ECG-SPECT-coronary 483 
angiography to ECG-coronary angiography was £2473; from ECG-coronary 484 
angiography to SPECT-coronary angiography was £4032 and from SPECT-coronary 485 
angiography to coronary angiography strategy £3372. In this case the ECG-coronary 486 
angiography and coronary angiography strategies have extended dominance over 487 
the SPECT-coronary angiography strategy (ICER: £5,200). Finally, for an 85% 488 
prevalence level the ICERs for the movement between strategies are further reduced 489 
and ECG-coronary angiography and coronary angiography strategies continue to 490 
have extended dominance over the SPECT-coronary angiography strategy.  491 
 492 
[Table 2 Estimated costs and outcomes for each diagnostic strategy] [HERE] 493 
 494 
 Sensitivity Analysis 495 
From the probabilistic sensitivity analysis credible limits for costs and QALYs for 496 
each strategy were obtained (Table 2). From these data, it was not immediately 497 
obvious if one strategy could dominate any of the others. Therefore, the probabilistic 498 
results were presented in a series of CEACs (Figure 3). 499 
 500 
In the base case analysis ECG-coronary angiography strategy is highly unlikely to be 501 
optimal (Figure 3a). Moreover, if the decision maker is willing to pay less than £8000 502 
for a QALY the strategy with higher probability of being optimal is ECG-SPECT-503 
coronary angiography. At approximately £9000 per QALY, ECG-SPECT-coronary 504 
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angiography and SPECT-coronary angiography strategies have a similar probability 505 
of being optimal.  At ceiling ratio of £20,000 SPECT-coronary angiography has a 90% 506 
likelihood of being considered the more cost effective option, but beyond this value, 507 
the likelihood falls such that at willingness to pay values over £75,000 coronary 508 
angiography is the strategy most likely to be optimal. 509 
 510 
At a 30% prevalence of disease (Figure 3b), strategies that involve SPECT seem to be 511 
optimal for decision makers willingness to pay for a QALY of up to £20,000; coronary 512 
angiography being the optimal strategy decision for higher values of willingness to 513 
pay for a QALY. For higher levels of prevalence of disease and for a threshold of 514 
more than a £10,000 per QALY, coronary angiography is the optimal decision (Figure 515 
3c and 3d). 516 
 517 
On the basis of sensitivity analysis on the model parameters (not reported) the model 518 
results were found to be more sensitive to the prevalence of disease (Figure 3) and 519 
tests performance. The values used in the model for sensitivity and specificity of tests 520 
were similar to those used in previous studies.(12) If other central values than those 521 
used in the base case were chosen the model might produce very different results. As 522 
there was known to be heterogeneity in the data other sources of specificity and 523 
sensitivity data were used for ECG and SPECT. These data were based on De and 524 
colleagues(42) as an example of a scenario where SPECT performs poorly and from 525 
Michaelides and colleagues(43) for a well performing SPECT scenario. As expected, 526 
in the worst SPECT performance scenario, SPECT-coronary angiography strategy did 527 
not appear in the frontier of optimal solutions for any level of prevalence of disease, 528 
while ECG-SPECT-coronary angiography strategy appears optimal for 10.5% 529 
prevalence of disease and when the threshold is less than £5,000. Using data from 530 
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Michaelides and colleagues gave similar results to those presented in the base case 531 
(Figure 3).  It should be noted that even for this most optimistic scenario, at a level of 532 
prevalence higher than 60% and a threshold over £16,000 per QALY, the coronary 533 
angiography strategy appears to be the optimal diagnostic strategy. 534 
 535 
With respect to changes in the time horizon adopted for the analysis, it was found 536 
that as the time horizon reduces the incremental cost per QALY increases.  This is 537 
because the costs of initial diagnosis and treatment are not offset by survival and 538 
quality of life gains.  Increasing the likelihood that misdiagnoses will be rectified 539 
reduces the penalty associated with making a false negative diagnosis (i.e. it 540 
improves the cost-effectiveness of non-invasive strategies compared with coronary 541 
angiography).  With respect to use of the higher values for ECG indeterminacy and 542 
lower value for SPECT indeterminacy it was found that SPECT strategies were more 543 
likely to be considered cost-effective.  The results of the analysis were relatively 544 
insensitive to the alternative cost data used and to the changes considered in the 545 
probability distributions for the sensitivity and specificity of coronary angiography 546 
sensitivity and specificity.  Furthermore, for the sub-group analysis restricted to 547 
women it was found that the results were slightly more favourable to SPECT based 548 
strategies.  549 
 550 
When strategies involving ECHO were added to the model using data from 551 
Kuntz(12), they were shown to be potentially cost-effective options. Furthermore, at a 552 
10.5% prevalence of CAD, ECHO-SPECT-coronary angiography strategy dominated 553 
both ECG-SPECT-coronary angiography and ECG-SPECT strategies, while ECHO-554 
coronary angiography dominated both ECG-coronary angiography and SPECT-555 
coronary angiography strategies.   556 
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 557 
At low levels of prevalence of CAD up to 1%, the strategy ECG-SPECT-coronary 558 
angiography dominated all others, for prevalences between 1% and 4%  SPECT 559 
based strategies dominated non-SPECT based strategies while at 5% only SPECT-560 
coronary angiography strategy dominated coronary angiography strategy. 561 
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DISCUSSION 562 
 563 
This analysis indicates that it is possible that the incremental cost per unit of QALY 564 
for the move from stress ECG-SPECT-coronary angiography to SPECT-coronary 565 
angiography might be considered worthwhile when the prevalence of CAD is below 566 
30%. A combination of ECG-SPECT-coronary angiography and SPECT-coronary 567 
angiography strategies would be more efficient than a reliance on a strategy of ECG-568 
coronary angiography only at these levels of prevalence of disease. Probabilistic 569 
sensitivity analysis suggests that the ECG-coronary angiography strategy is highly 570 
unlikely to be the most cost effective and does not form part of the cost-effectiveness 571 
efficiency frontier described by the CEACs. The coronary angiography option is 572 
more likely to be considered optimal at high levels of prevalence of disease (>30%), 573 
but at lower levels of prevalence of disease, SPECT-coronary angiography strategy is 574 
more likely to be considered optimal. This result should be compared with the 575 
deterministic studies, which frequently concluded that strategies including SPECT 576 
were the most cost-effective. However, there is no consensus in the literature on 577 
which strategy was more cost-effective. For example, three studies compared SPECT-578 
coronary angiography and stress ECG-SPECT-coronary angiography and two 579 
concluded that stress ECG-SPECT-coronary angiography was cost-effective(13, 24) 580 
and one reported that the extra benefits provided by SPECT-coronary angiography 581 
might be worth its additional cost.(44)  582 
 583 
The model considered some of the strategies that are potentially relevant for 584 
managing CAD patients.  The effectiveness data for the diagnostic tests came from a 585 
systematic review of diagnostic and prognostic studies conducted by Mowatt and 586 
colleagues.(4)  However, little data were available from the UK. As a result data from 587 
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other countries were used, much of which came from studies conducted in the USA. 588 
In these cases, relative risks and rates of utilisation were extrapolated but absolute 589 
rates of utilisation of interventions were not, as it is well known that there are 590 
differences in utilisation rates between the USA and UK and it was believed that the 591 
use of relative rates would result in less bias. 592 
  593 
Positron emission tomography (PET) or stress Echocardiography (ECHO) 594 
interventions were not included in the original model. Other economic evaluations 595 
have shown PET as being unlikely to be cost-effective(4) and for the UK and other 596 
countries it has very limited availability.  ECHO is, however, a potentially relevant 597 
alternative and its omission from the original analysis represents a limitation of the 598 
study.  Evidence suggests that this approach may be a viable alternative(4) but it was 599 
excluded by NICE from their consideration of this technology (which the research 600 
presented in this paper was originally commissioned to inform).  Then, ECHO based 601 
strategies were explored in sensitivity analysis and, using data from Kuntz(12) they 602 
show to be potentially cost effective options. However, these results should be 603 
treated with caution as the data on sensitivity and specificity used were based on an 604 
ad-hoc review of the literature and indirect test comparisons. The other sensitivity 605 
and specificity data for the other tests were based on systematic review that included 606 
studies with direct test comparisons, and a meta analysis. Moreover, Mowatt and 607 
colleagues(4)  sensitivities and specificities for the other tests show to be lower than 608 
those observed in the article by Kuntz and colleagues.(12) This would tend to 609 
magnify the favorable results obtained for ECHO.  610 
 611 
The ‘do nothing’ strategy was not considered in the model. This option might be 612 
relevant to a situation where diagnosis was made on the basis of clinical examination 613 
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only. Generally, some form of diagnostic testing is performed within the UK, as well 614 
as in other settings, and as a result this option was judged to be inappropriate for this 615 
evaluation. 616 
 617 
In the base case model it was assumed that those patients who were not correctly 618 
classified would be correctly diagnosed within 10 years. If the assumed period were 619 
shorter, then those strategies that result in incorrect diagnoses would not be as 620 
heavily penalised, and ECG-coronary angiography strategy, for instance, would 621 
perform better. 622 
 623 
The model allows for indeterminate results in ECG and SPECT but it does not allow 624 
for a second ECG or SPECT test after indeterminacy. Moreover, complications due to 625 
any of the tests were not considered and hence there were no quality of life 626 
adjustment for these. This might be a potentially significant caveat as the 627 
complications from coronary angiography (i.e. stroke) are likely to be more 628 
important than in the other tests. This would tend to reduce the cost-effectiveness of 629 
those strategies that make the most use of coronary angiography. 630 
 631 
As was stated above, the main results showed that key parameters in this model 632 
were prevalence of disease and tests performance. Sensitivity analyses were carried 633 
out considering prevalence rates below the base case analysis rates (10.5%) according 634 
to professional guidelines medium and low risk rate stratification.(41) The model 635 
results are in line with those professional bodies recommendations. In other words, a 636 
stepwise approach with less invasive test as first option followed by more invasive 637 
ones in comparison with a more invasive test as first option.  638 
 639 
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The values for sensitivity and specificities for SPECT and ECG in this study are lower 640 
than those presented elsewhere.(41) The data used here are based on a more robust 641 
approach as they are based on studies that made direct comparisons between the 642 
diagnostic tests.(4) This approach might lead to less data being included as a more 643 
restrictive inclusion criteria is used, but has higher internal validity.  Despite our best 644 
efforts to obtain high quality data for sensitivities and specificities the results were 645 
still uncertain.  In our analysis this uncertainty has been modelled in two ways.  646 
Firstly, statistical distributions have been defined for these variables and the effect of 647 
using these distributions has been estimated in the probabilistic sensitivity analysis.  648 
Secondly, we have explored the use of fundamentally different values for these 649 
parameters in best case and worst case scenarios.  The results of these analyses were 650 
as expected.  For the worst SPECT scenario non-SPECT strategies represented the 651 
optimal decision, but it should be noted that the accuracy of SPECT reported in De 652 
and colleagues, used in the worst case scenario for SPECT, is quite different from that 653 
shown by other studies.(4) Using data from Michaelides and colleagues(43) as an 654 
example of best SPECT performance scenario provided similar results to the base 655 
case analysis.  However, for high level of prevalence of disease (>60%) the coronary 656 
angiography strategy appears to be the optimal decision.  657 
 658 
Conclusions about the role of coronary angiography might change if the assumption 659 
is not made that coronary angiography is a gold standard.  It is very difficult to 660 
assess the effect of relaxing this assumption as the sensitivity and specificity of the 661 
other tests would need adjusting as they are compared to coronary angiography.  662 
Furthermore, it is possible that SPECT might have independent prognostic value 663 
over coronary angiography.(45)  The sensitivity analysis that was conducted was 664 
unable to fully address these issues but as it reduced the performance of coronary 665 
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angiography compared with the other tests it can be thought of as reflecting a worst 666 
case situation for the performance of coronary angiography.  Nonetheless, results 667 
were insensitive to the changes to considered. 668 
 669 
Linking diagnostic performance to long-term outcomes required a number of 670 
assumptions to be made about both the structure of the model and its parameters.  671 
Some of these assumptions were based on a limited evidence base and it is unclear 672 
whether these data are applicable to the UK or to other settings.  Furthermore, due to 673 
the absence of data, the model presented does not allow for higher quality of life 674 
after revascularisation. Therefore, the benefits of revascularisation are derived solely 675 
from higher life expectancy.  If a higher quality of life were achieved after 676 
revascularisation, those strategies that accurately identify patients for 677 
revascularisation (fewer false negatives) would perform better.  678 
 679 
A further caveat, related to the pay-off model, is the extent to which severity of 680 
disease is linked to quality of life.  The model presented, and many of the previous 681 
evaluations, makes the assumption that there is a direct link.  No utility data were 682 
identified with which to test this assumption and, therefore, further research is 683 
required on this area. 684 
 685 
Finally, the adoption of SPECT based strategies might reduce the necessary time for 686 
diagnosis as in some countries the waiting time from a positive stress ECG result to a 687 
coronary angiography may be considerable. In the UK, for instance, this waiting time 688 
is currently about 20 weeks.(4)  The increase use of SPECT in rapid access clinics 689 
could reduce the distress associated with this wait. Moreover, within the UK and 690 
other countries SPECT may possibly not be as widely available as stress ECG.  691 
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Therefore, patients who require SPECT may need to travel and to support the time 692 
and financial costs associated with this. Clearly, the expansion of SPECT-based 693 
services would require considerable investment in infrastructure. Although the cost 694 
of this expansion might be important, the lack of trained staff could be a greater 695 
obstacle. In the UK, for instance, this trained staff expansion would take between 5 696 
and 10 years.(4)   697 
 698 
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CONCLUSIONS 699 
 700 
Strategies that involve the use of SPECT seem to be optimal for low levels of 701 
prevalence of CHD and should they be adopted this would reduce the number of 702 
invasive tests required. Although this higher use may be efficient, the expansion of 703 
services may be slow, because of the time needed to train staff adequately. For high 704 
levels of prevalence of CHD, the result seems to be the opposite; namely, strategies 705 
that do not involve SPECT seem to be optimal. Finally, future research should 706 
acknowledge that determining the optimal diagnosis strategy requires information 707 
on longer-term outcomes, especially on rates of service utilisation and on utilities. 708 
Sensitivity analyses show strategies that involved ECHO as potentially cost-effective 709 
options. Further research to assess the relative cost-effectiveness of ECHO should 710 
also be performed. 711 
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Table 1: Summary of variables used in the analysis 849 
Probabilities Parameter 
value 
 Source Probability Distribution 
and parameter values 
Males 10.5 10.5 – 90 BrHF Stats 2003(1)  Prevalence of disease for 
patient cohorts Females 5.5 5.5 – 90 BrHF Stats 2003(1)  
Stress ECG Sensitivity 0.66 0.42 – 0.92 Mowatt 2004(4) Beta: α=400; β=206 
 Specificity 0.60 0.43 – 0.83 Mowatt 2004(4) Beta: α=364; β=242 
 Indeterminacy 0.18  Patterson 1995(15) Beta: α=819; β=179 
 Mortality risk 0.00005  Patterson 1995(15) Gamma: scale=0.001; 
shape=2 
SPECT Sensitivity 0.83 0.63 – 0.93 Mowatt 2004(4) Beta: α=503; β=103 
 Specificity 0.59 0.44 – 0.90 Mowatt 2004(4) Beta: α=358; β=248 
 Indeterminacy 0.09  Patterson 1995(15) Beta: α=89; β=910 
 Mortality risk 0.00005  Patterson 1995(12, 
15) 
Gamma: scale=0.001; 
shape=2 
Coronary Angiography Sensitivity 1  Assumption  
 Specificity 1  Assumption  
 Mortality risk 0.0015  Patterson 1995(15) Gamma: scale=1; shape=0.05 
Mortality     
Annual rate for age X   Interim Life 
Tables(18)  
 
Relative Risk Medium Risk 2.3  Yusuf 1994(44) Lognormal: µ=0.833; σ=0.05 
Relative Risk High Risk 3.6  Yusuf 1994(44) Lognormal: µ=1.281; σ=0.05 
Risk of MI:     
Low Risk (& false positives) 2.5%  Shaw 1999(21) Beta: α=145; β=5681 
Untreated Medium Risk & false 
negative medium risk 
5.0%  Shaw 1999(21) Beta: α=291; β=5535 
High Risk & false negative high risk 9.0%  Shaw 1999(21) Beta: α=524; β=5302 
Prop non-fatal MI 55.16%  Based on Lampe 
2000(20) and 
Volmink 1998(22) 
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False Negative Results   Kuntz 1999(12)  
Prop to High Risk 59%   Beta: α=590; β=409 
Revascularisation:     
Proportion revascularisation Low, 
Medium, High risk. 
5%; 50%; 
100% 
 Assumption Low: Beta: α=50; β=950 
Medium: Beta: α=500; β=500 
High: Beta: α=900; β=100 
Prop PTCA low, medium and high risk 
respectively 
90%; 61%; 
10% 
 BrHF Stats 2003(1) 
for medium risk. 
Assumption for 
low and high risk 
Low: Beta: α=900; β=100 
Medium: Beta: α=610; β=390 
High: Beta: α=100; β=900 
Prop of patients with 2nd 
revascularisation 
    
 PTCA 3.6%  Kuntz 1999(12) Gamma: α=0.036; λ=1 
 CABG 1.8%  Kuntz 1999(12) Gamma: α=0.018; λ=1 
Mortality Risk reduction from revasc:     
High Risk 57%  Kuntz 1999(12) Lognormal: µ=-0.562; σ=0.14 
Medium Risk 15%  Kuntz 1999(12) Lognormal: µ=-1.95; σ=0.32 
Risk reduction of MI:     
PTCA 17%  Kuntz 1999(12) Lognormal: µ=-1.772; σ=0.10 
CABG 40%  Kuntz 1999(12) Lognormal: µ=-0.99; σ=0.02 
Procedures mortality     
PTCA 0.75%  Kuntz 1999(12) Gamma: α=0.075; λ=1 
CABG 3.1%  Kuntz 1999(12) Gamma: α=0.031; λ=1 
Costs Total Cost 
(2001/02 £ 
sterling) 
 Source  
Stress ECG 104.86  Hartwell 2003(23) Tri: 25-225 
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SPECT  261.91  Underwood 
1999(24) (1996/97 
prices) 
Tri: 128-340 
Coronary Angiography 1,309.55  Underwood 
1999(24) `(1996/97 
prices) 
Tri: 895-1724 
Medical Management 311.00  Mowatt 2004(4)  
MI 1,122.00  NHS Cost 2001/02  
 
Tri: 761-1627 
PTCA 1,993.74  Hartwell 2003(23) Tri: 1346-2568 
CABG 4,397.00  NHS Cost 2001/02 
 
Tri: 3005-5289 
Utility Value  Source  
Low Risk 0.87  Kuntz 1999(12) Beta: α=184; β=27 
Medium Risk 0.81  Kuntz 1999(12) Beta: α=171; β=40 
High Risk 0.67  Kuntz 1999(12) Beta: α=141; β=70 
Adjustment for revascularisation or MI 0.1  Assumption Beta: α=21; β=190 
Other parameters     
Age at start of model 60 years    
Time horizon 25 years    
 850 
 851 
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Table 2: Estimated costs and outcomes for each diagnostic strategy 852 
Strategy 
Cost 
(95% CI) 
QALYs 
(95% CI) ICERs 
Prevalence 10.5% Basecase    
ECG-SPECT-Coronary 
Angiography £5,192 12.510  
 (4,906-5,473) (11.902-13.051)  
ECG-Coronary Angiography  £5,396 12.518 £26,249 
 (5,081-5,722) (11.907-13.066)  
SPECT-Coronary Angiography  £5,529 12.532 £9,261 
 (5,183-5,821) (11.930-13.084)  
Coronary Angiography £5,929 12.541 £48,576 
 (5,505-6,345) (11.926-13.089)  
    
Prevalence 30%    
ECG-SPECT-Coronary 
Angiography  £5,787 11.727  
 (5,506-6,070) (11.235-12.173)  
ECG-Coronary Angiography  £5,958 11.759 £5,454 
 (5,647-6,297) (11.270-12.215)  
SPECT-Coronary Angiography  £6,155 11.798 £4,997 
 (5,793-6,471) (11.310-12.264)  
Coronary Angiography £6,484 11.840 £7,893 
 (6,052-6,926) (11.330-12.311)  
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Prevalence 50%    
ECG-SPECT-Coronary 
Angiography  £6,397 10.924  
 (6,068-6,709) (10.524-11.294)  
ECG-Coronary Angiography  £6,535 10.979 £2,473 
 (6,167-6,906) (10.578-11.367)  
SPECT-Coronary Angiography  £6,797 11.045 £4,032 
 (6,356-7,168) (10.631-11.455)  
Coronary Angiography £7,053 11.121 £3,372 
 (6,539-7,551) (10.668-11.551)  
    
Prevalence 85%    
ECG-SPECT-Coronary 
Angiography  £7,464 9.518  
 (7,002-7,917) (9.146-9.862)  
ECG-Coronary Angiography  £7,543 9.616 £803 
 (7,034-8,060) (9.219-9.994)  
SPECT-Coronary Angiography  £7,921 9.726 £3,428 
 (7,306-8,469) (9.284-10.147)  
Coronary Angiography £8,049 9.862 £948 
 (7,364-8,726) (9.330-10.337)  
ECG = stress electrocardiography; SPECT = single photon emission computed tomography 853 
myocardial perfusion scintigraphy, CI = credible interval 854 
* ICER against ECG-SPECT-Coronary Angiography strategy: for 10.5% prevalence rate of 855 
CAD = £15,241; for 30% prevalence rate = £5,200 856 
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** ICER against SPECT-Coronary Angiography strategy: for 50% prevalence rate of CAD = 857 
£3,677; for 85% prevalence rate of CAD = £2,057 858 
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Figure 1: Decision Tree Model (short term diagnosis model) 859 
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 860 
Stepwise approach: if first test inconclusive or positive result, a further test looking for more 861 
information is performed. ECG = stress electrocardiography; SPECT = single photon emission 862 
computed tomography myocardial perfusion scintigraphy; CA= coronary angiography. In 863 
brackets (i.e. ‘False Positive (Low Risk)’) the true state of the disease.  864 
 865 
Figure 2: Simple Markov Model for Prognosis and Management of CHD  866 
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 867 
In brackets (i.e. ‘False Positive (Low Risk)’) the true state of the disease. All states considered 868 
MI and revascularisation quality of life and cost effects. Revascularisation effects lasts more 869 
than one cycle so modelled as state. 870 
Figure 3a: Cost-effectiveness acceptability curves: prevalence of CAD = 10.5% 871 
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 872 
ECG = stress electrocardiography; SPECT = single photon emission computed tomography myocardial perfusion scintigraphy; CA= coronary angiography 873 
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Figure 3b: Cost-effectiveness acceptability curves: prevalence of CAD =30% 874 
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 875 
ECG = stress electrocardiography; SPECT = single photon emission computed tomography myocardial perfusion scintigraphy; CA= coronary angiography 876 
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Figure 3c: Cost-effectiveness acceptability curves: prevalence of CAD = 50% 877 
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 878 
ECG = stress electrocardiography; SPECT = single photon emission computed tomography myocardial perfusion scintigraphy; CA= coronary angiography 879 
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Figure 3d: Cost-effectiveness acceptability curves: prevalence of CAD = 85% 880 
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 881 
ECG = stress electrocardiography; SPECT = single photon emission computed tomography myocardial perfusion scintigraphy; CA= coronary angiography 882 
 883 
